These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25934386)

  • 1. Stratified medicine in inflammatory disorders: From theory to practice.
    Arron JR; Townsend MJ; Keir ME; Yaspan BL; Chan AC
    Clin Immunol; 2015 Nov; 161(1):11-22. PubMed ID: 25934386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis.
    Andrisani G; Gremese E; Guidi L; Papa A; Marzo M; Felice C; Pugliese D; Armuzzi A
    Reumatismo; 2013 May; 65(2):75-8. PubMed ID: 23877411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early patient stratification and predictive biomarkers in drug discovery and development: a case study of ulcerative colitis anti-TNF therapy.
    Laifenfeld D; Drubin DA; Catlett NL; Park JS; Van Hooser AA; Frushour BP; de Graaf D; Fryburg DA; Deehan R
    Adv Exp Med Biol; 2012; 736():645-53. PubMed ID: 22161357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomolecular markers in assessment and treatment of asthma.
    Fatemi F; Sadroddiny E; Gheibi A; Mohammadi Farsani T; Kardar GA
    Respirology; 2014 May; 19(4):514-23. PubMed ID: 24698542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.
    Christensen KR; Steenholdt C; Brynskov J
    Scand J Gastroenterol; 2015 Aug; 50(8):1018-24. PubMed ID: 25861832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab in ulcerative colitis: ready for prime time.
    Danese S
    Dig Liver Dis; 2013 Jan; 45(1):8-13. PubMed ID: 22766323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economics of adalimumab for ulcerative colitis.
    Xie F
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):373-7. PubMed ID: 25817776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab for the treatment of ulcerative colitis.
    Eshuis EJ; Bemelman WA; Stokkers PC
    Expert Rev Gastroenterol Hepatol; 2009 Jun; 3(3):219-29. PubMed ID: 19485804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
    Lee TW; Fedorak RN
    Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J
    Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Studies on the control of inflammation in acute and chronic inflammatory disease].
    Feyen H; Hiemeyer V
    Verh Dtsch Ges Inn Med; 1969; 75():923-6. PubMed ID: 5401669
    [No Abstract]   [Full Text] [Related]  

  • 12. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab.
    Taxonera C; Estellés J; Fernández-Blanco I; Merino O; Marín-Jiménez I; Barreiro-de Acosta M; Saro C; García-Sánchez V; Gento E; Bastida G; Gisbert JP; Vera I; Martinez-Montiel P; Garcia-Morán S; Sánchez MC; Mendoza JL
    Aliment Pharmacol Ther; 2011 Feb; 33(3):340-8. PubMed ID: 21133961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-inflammatory effect of PPARgamma agonists: basics and clinical applications].
    Wada K; Kamisaki Y
    Nihon Rinsho; 2010 Feb; 68(2):278-83. PubMed ID: 20158097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB
    Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Introduction to biological drugs].
    Fernández-Cruz E; Alecsandru D; Rodríguez-Sainz C
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():2-6. PubMed ID: 19080985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature.
    Peyrin-Biroulet L
    Am J Gastroenterol; 2013 May; 108(5):859-60. PubMed ID: 23644972
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low prevalence of antibodies to cyclic citrullinated peptide in patients with inflammatory bowel disease regardless of the presence of arthritis.
    Papamichael K; Tsirogianni A; Papasteriades C; Mantzaris GJ
    Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):705-9. PubMed ID: 19525851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of herbal preparations in the treatment of oxidant-mediated inflammatory disorders.
    Kaplan M; Mutlu EA; Benson M; Fields JZ; Banan A; Keshavarzian A
    Complement Ther Med; 2007 Sep; 15(3):207-16. PubMed ID: 17709066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.